肥胖减重手术人群高危MASH无创评分FMO的开发与验证
基于5个减重手术队列共1961例肝活检者开发并验证FMO评分,纳入AST、ALT、甘油三酯和HDL-C。FMO在推导队列AUROC为0.874,外部验证AUROC为0.803-0.874,UK Biobank和NHANES验证AUROC分别为0.753和0.866。该评分可有效识别肥胖人群中的高危MASH。
要点
- FMO评分由AST、ALT、甘油三酯和HDL-C四项常规指标构成。
- 推导队列AUROC为0.874,外部验证AUROC为0.803-0.874。
- 推导队列排除切点0.05敏感性≥0.90、NPV 0.976,纳入切点0.22特异性≥0.90、PPV 0.481。
核心结论
- FMO是识别肥胖人群高危MASH的准确且经济的无创评分。
研究设计与样本
- 使用5个独立减重手术队列共1961例肝活检者的数据,推导队列n=1095,外部验证队列n=866(4个活检确认队列)。
- 另在UK Biobank超重/肥胖队列(n=15,745)和NHANES数据库(n=1573)中进行验证。
- 在UK Biobank亚队列(n=1955,中位随访13.7年)评估对严重肝脏相关结局(SLROs)的预测价值。
主要发现
- FMO在推导队列AUROC=0.874(95% CI 0.844-0.905),全国外部验证队列AUROC=0.803-0.874。
- NHANES和UK Biobank全球验证AUROC分别为0.866和0.753。
- 纵向分析证实对SLROs的预测,Harrell C-index=0.703。
- 推导队列排除切点0.05敏感性≥0.90、NPV 0.976;纳入切点0.22特异性≥0.90、PPV 0.481。
- 外部验证NPV为0.907-1.00,PPV为0.333-0.630。
关键数值与推荐
- FMO评分包含天冬氨酸氨基转移酶、丙氨酸氨基转移酶、甘油三酯和高密度脂蛋白胆固醇。
- 推导队列排除切点0.05,敏感性≥0.90,NPV 0.976;纳入切点0.22,特异性≥0.90,PPV 0.481。
临床怎么用
- 在肥胖人群(尤其减重手术候选者)中可用FMO评分无创识别高危MASH,减少肝活检需求。
- FMO评分仅需常规临床指标,成本低,适合筛查场景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: At-risk metabolic dysfunction-associated steatohepatitis (MASH) elevates risks of liver-related and all-cause morbidity and mortality. We developed and validated a noninvasive score using routine clinical indicators to identify at-risk MASH in obesity. APPROACH AND RESULTS: Using data from 1961 individuals across 5 independent bariatric cohorts with liver biopsy, we developed the predictive score in 1 derivation cohort (n=1095), performed internal validation (bootstrapping), and conducted external validation using the remaining 4 biopsy-confirmed cohorts (n=866). The score was also validated in the international overweight/obese cohorts from the UK Biobank (n=15,745) and NHANES database (n=1573). Predictive value for severe liver-related outcomes (SLROs, including cirrhosis, hepatocellular carcinoma, etc) was assessed in a UK Biobank subcohort (n=1955; median 13.7-year follow-up). Head-to-head comparisons with existing indices were performed. The predictive model, designated as FMO (Fibrotic/at-risk MASH in Obesity), incorporated aspartate aminotransferase, alanine aminotransferase, triglyceride, and high-density lipoprotein cholesterol. The FMO model demonstrated robust discrimination in derivation (AUROC=0.874, 95% CI 0.844-0.905) and nationwide external validation cohorts (AUROCs=0.803-0.874), and in global validation in both NHANES and UK Biobank (AUROCs=0.866 and 0.753, respectively). Longitudinal analysis confirmed SLRO's prediction (the Harrell C-index=0.703). In the derivation cohort, the FMO model demonstrated optimal rule-out [cutoff 0.05, sensitivity ≥0.90, negative predictive value (NPV) 0.976] and rule-in [cutoff 0.22, specificity ≥0.90, positive predictive value (PPV) 0.481] performance. External validation showed NPVs of 0.907-1.00 and PPVs of 0.333-0.630. Comparative analyses revealed superior diagnostic performance of the FMO model versus some existing models. CONCLUSIONS: The FMO is an accurate and cost-effective noninvasive score for at-risk MASH identification in populations with obesity.
引用
- Huang X, Zhu T, Li S, et al. Development and validation of a noninvasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery. Hepatology. 2025. PMID: 41231578. doi:10.1097/HEP.0000000000001612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。